Trevi Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Trevi Therapeutics, Inc. (TRVI) had Debt Securities, Available-for-sale, Amortized Cost of $264.99 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $264.99M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $152.56M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $169.20M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $138.03M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2026-06-30 | $264.99M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $152.56M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $169.20M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $138.03M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $86.80M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $83.81M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $73.46M 10-K · filed 2026-03-17 |
| 2024-09-30 | $49.30M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $56.62M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $59.08M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $50.60M 10-K · filed 2025-03-18 |
| 2023-09-30 | $63.12M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $80.65M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $99.69M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $108.04M 10-K · filed 2024-03-20 |
| 2022-09-30 | $59.29M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $54.29M 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |